November 2, 2016
European Patent Office OKs new patent for Allergy Therapeutics’ Microcrystalline Tyrosine tech
European Patent Office OKs new patent for Allergy Therapeutics’ Microcrystalline Tyrosine tech
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Manuel Llobet
November 30, 2015
Allergy Therapeutics completes patient enrolment in PQBirch204 Phase II study (Allergic rhinitis)
Allergy Therapeutics, a UK-based specialist in allergy vaccines, has completed randomization with 364 patients entered into the PQBirch204 double-blind, placebo-controlled dose selection study for the specific subcutaneous immunotherapy (SCIT), Pollinex Quattro Birch.